Predicting stroke and death in patients with heart failure using CHA₂DS₂-VASc score in Asia

Mi Kyoung Son¹, Nam-Kyoo Lim¹ and Hyun-Young Park²*

Abstract

Background: The CHA₂DS₂-VASc score is used to assess risk of mortality as well as to stratify risk of stroke in patients with atrial fibrillation (AF). This study evaluated whether CHA₂DS₂-VASc score was predictive of 1 and 2 year risks of stroke and death in Asian patients with heart failure (HF).

Methods: Patients hospitalized for HF were enrolled in the Korean Acute Heart Failure (KorAHF) registry, a prospective observational multicenter cohort study, between March 2011 and February 2014. Patients with a history of cancer before hospitalization for HF were excluded. The discriminatory properties of the CHA₂DS₂-VASc score were quantified using C-statistics.

Results: The study included 5158 patients with HF, 2091 with and 3067 without AF. Rates of stroke in these two groups were 4.5 and 2.8%, respectively, after 1 year, and 5.5 and 3.4%, respectively, after 2 years. Each 1-point increase in CHA₂DS₂-VASc score was associated with significantly increased risks of stroke and all-cause death in HF patients with and without AF (p-value < 0.05). The C-statistics of the CHA₂DS₂-VASc score for all-cause death in patients with and without AF were 0.600 and 0.630, respectively, at 1 year and 0.626 and 0.635, respectively, at 2 years. The C-statistics for stroke ranged from 0.593 to 0.639.

Conclusions: Among patients with incident HF with and without AF, CHA₂DS₂-VASc score was significantly associated with the risks of stroke and death. However, CHA₂DS₂-VASc score was only a modest predictor of stroke and death, indicating the need for studies evaluating modified CHA₂DS₂-VASc scores. The majority of strokes occurred relatively shortly after hospitalization for HF and that mortality rates in patients with HF remain high. Thus, early treatment after HF to prevent stroke is essential.

Keywords: Heart failure, Stroke, Atrial fibrillation, CHA₂DS₂-VASc score

Background

Heart failure (HF) occurs when the heart is unable to supply sufficient blood to the body, due to a structural and/or functional cardiac abnormality, resulting in reduced cardiac output and/or elevated intracardiac pressures at rest or during stress [1]. Atrial fibrillation (AF) is the most common sustained arrhythmia observed in clinical practice [2], and has been associated with a 5-fold higher risk of stroke compared with the general population [3]. The risk of ischemic stroke within 1 month after a diagnosis of HF was also found to be increased more than 5-fold [4], indicating that both HF and AF are associated with increased risks of ischemic stroke and mortality [3–7].

The CHA₂DS₂-VASc score is calculated from various factors, including congestive HF, hypertension, age ≥ 75 years (doubled risk), diabetes, stroke/transient ischemic attack/thromboembolism (doubled), vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque), age 65–74 years, and female sex [8]. This simple clinical risk score is commonly used to stratify the risk of stroke in patients with AF [9].

The clinical utility of the CHA₂DS₂-VASc score in predicting the risks of ischemic stroke, thromboembolism, and death has extended beyond subjects without AF [10, 11].
For example, the CHA2DS2-VASc score was shown to predict the risks of ischemic stroke, thromboembolism, and death in patients with incident HF with or without AF [12]. Moreover, the predictive accuracy of the CHA2DS2-VASc score for death and stroke was reported to be modest in patients with systolic HF in sinus rhythm [13]. These findings suggested that CHA2DS2-VASc score can be used to stratify patients with systolic HF in sinus rhythm [13]. These findings are consistent with those of a previous study [14].

It is necessary to assess the performance of the CHA2DS2-VASc score in Asian patients with HF, where the CHA2DS2-VASc score has not yet been determined. Because the risks for stroke and death in patients with HF vary by racial/ethnic groups, it is necessary to assess the performance of the CHA2DS2-VASc score in Asian patients with HF [4, 5, 12, 13]. This study therefore evaluated whether CHA2DS2-VASc predicts stroke and death in patients with HF with and without AF, in the Korean Acute Heart Failure (KorAHF) registry.

Methods

Data source

This study utilized the KorAHF registry, an ongoing, prospective observational multicenter cohort study, that has enrolled patients hospitalized for acute HF at 10 tertiary university hospitals across the country from March 2011 to February 2014 [14, 15]. This registry consists of 5625 patients diagnosed with HF by clinician and either (i) lung congestion, defined as “congestion” on chest X-rays or as rales on physical examination, or (ii) objective findings of left ventricular (LV) systolic dysfunction or structural heart disease. Real-time administrative data were collected using the Internet-based Clinical Research and Trial Management System (iCReaT), supported by the Korean National Institute of Health (KNIH). Information on a patient’s demographic characteristics, eligibility evaluation, clinical history, symptoms, physical measurements, electrocardiographic findings, medications, additional treatments, complications, and outcomes were documented at admission and during the follow-up. The study design, data validation, and interim analysis of this registry have been reported [14, 15]. The study protocol was approved by the Institutional Review Board of each hospital. Written informed consent was obtained from each patient, or from a relative or legal representative. All patients, except death, were followed up for at least 2 years, and data were collected through November 30, 2016.

Study population

Of 5625 patients hospitalized for HF, 467 with a history of cancer before hospitalization for HF were excluded. Thus, the study cohort consisted of 5158 patients with HF, 2091 with and 3067 without AF (Fig. 1).

The CHA2DS2-VASc score for each patient was calculated as described [8]. Patients with HF only and no additional risk factors for stroke were assigned a CHA2DS2-VASc score of 1. The CHA2DS2-VASc score was considered a categorical variable, classified as scores of 1, 2, 3, 4, 5, 6, and ≥7, to calculate the incidence rates for stroke and death. The CHA2DS2-VASc score was also considered a continuous variable to assess its ability to predict stroke and death. Medications used before hospital discharge were analyzed. Information on stroke and all-cause mortality was recorded during follow-up.

Statistical analysis

Baseline characteristics at the time of hospitalization for HF were described using means and standard deviations for continuous variables and percentages for categorical variables. The rates of stroke and all-cause death were calculated as the number of patients with stroke and death during the follow-up period, divided by the total person-years at risk, and were reported as number of patients per 100 person-years.

The association between CHA2DS2-VASc score and each outcome was determined by Cox’s proportional hazard regression analyses, performed after adjusting for potential confounders. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. Also, competing risk regression analysis using the Fine and Gray model was performed, taking into account the high mortality rate of patients with acute HF [16]. The discriminatory properties of the CHA2DS2-VASc score were quantified using the area under the receiver-operating characteristic (ROC) curve (AUC) and time-dependent AUC [17]. The AUC and 95% CI for each endpoint were calculated by non-parametric methods. Time-dependent AUC was considered the probability that a randomly selected patient who experienced the event of interest before a given time had a higher risk score than a control patient who did not experience that event before a given time. Time-dependent AUC was calculated for 1 and 2 year follow-up, and their 95% CIs were obtained by bootstrapping using 1000 bootstrap samples.

All statistical tests were two-tailed, and p-values of < 0.05 were considered statistically significant. All statistical analyses were performed using SAS software (ver. 9.4; SAS Institute, Cary, NC, USA) and R version 3.6.1 (R Foundation for Statistical Computing) with the timeROC and crr packages [18, 19].

Results

The baseline characteristics of the study participants, with and without AF, are presented in Table 1. Most patients were older than 60 years of age (75.7%) and had hypertension (62.6%). Compared with patients with HF alone, those with HF and AF were older and significantly more likely to have had a previous stroke (19.6% vs. 12.4%), valvular heart disease (VHD) (29.1% vs. 12.5%), and chronic obstructive pulmonary disease (COPD)
(12.0% vs. 10.1%); to be a never smoker (65.5% vs. 58.0%); and to have been treated with an aldosterone antagonist (59.1% vs. 53.9%), loop diuretics (94.0% vs. 89.9%), digoxin (54.6% vs. 18.5%), and warfarin (60.6% vs. 13.1%). By contrast, the HF patients without AF were more likely to have diabetes mellitus (44.4% vs. 34.4%), previous chronic renal failure (15.4% vs. 12.4%), ischemic heart disease (IHD) (52.5% vs. 30.0%), and cardiomyopathy (29.3% vs. 24.3%); to be a current smoker (22.0% vs. 13.2%); and to have been treated with angiotensin-converting enzyme inhibitors (41.3% vs. 34.1%), angiotensin receptor blockers (47.1% vs. 44.3%), β-blockers (59.7% vs. 56.5%), aspirin (70.7% vs. 57.1%), and statins (53.9% vs. 37.3%).

Incidence rates for stroke and all-cause death after 1 and 2 years
During a mean follow-up of 2.3 years (up to 5.5 years), the rates of stroke in HF patients with and without AF were 7.0% ($n = 147$) and 4.1% ($n = 125$), respectively, and the rates of all-cause death were 38.7% ($n = 807$) and 37.2% ($n = 1141$), respectively (Additional file 1).

The overall incidence rates of stroke in the entire study cohort after 1 and 2 years were 4.4 and 3.0 per 100 person-years, respectively (Table 2). Incidence rates were generally attenuated (2.3/100 person-years) after 1 year of follow-up (Additional file 1), indicating that the majority of the events occurred relatively early after hospitalization for HF. Subgroup analyses showed that the incidence rates of stroke during the first year generally increased with increasing age. In patients with AF aged < 40 years and ≥ 80 years, the incidence rates of stroke were 2.6 and 8.6 per 100 person-years, respectively, whereas, in patients without AF, the incidence rates of stroke in these two age groups were 1.0 and 4.1 per 100 person-years, respectively. CHA2DS2-VASc scores of 1, 2, 3, 4, 5, 6, and ≥ 7 were associated with incidence rates of 5.3, 3.8, 3.2, 6.6, 5.7, 6.9, and 10.3 per 100 person-years, respectively, in patients with AF, and with incidence rates 4.0, 0.9, 4.0, 3.3, 3.8, 5.0, and 5.3 per 100 person-years, respectively, in patients without AF. Because patients with CHA2DS2-VASc scores of 1 were more likely to have cardiomyopathy than patients with CHA2DS2-VASc scores > 2, the high incidence rates of stroke in patients with CHA2DS2-VASc scores of 1 may result from underlying diseases such as cardiomyopathy (Additional file 2). Although the incidence rates of stroke were lower during the second year than the first year of follow-up, the incidence rates during the second year generally increased with increasing CHA2DS2-VASc score. As expected, the incidence of stroke was higher in patients with than without AF. The overall incidence rates of all-cause death in the entire study cohort after 1 and 2 years of follow-up were 26.2 and 20.5 per 100 person-years, respectively (Table 3). The incidence rate of all-cause death during the first year also generally increased with increasing age. In patients with AF aged < 40 and ≥ 80 years, the incidence rates of all-cause death were 10.1 and 43.6 per 100 person-years, respectively, whereas, in patients without AF, the incidence rates of all-cause death were 7.6 and 46.5 per 100 person-years, respectively. CHA2DS2-VASc scores of 1, 2, 3, 4, 5, 6, and ≥ 7 were associated with incidence rates of 14.6, 13.1, 22.1, 28.8, 28.0, 37.6, and 39.6 per 100 person-years, respectively, in patients with AF and with incidence rates of 11.0, 13.6, 17.6, 26.4, 32.7, 37.5, and 46.0 per 100 person-years, respectively, in patients without AF. The incidence rate of all-cause death was lower during the second than during the first year of follow-up, but it generally increased with increasing CHA2DS2-VASc score.
| Characteristics                        | Overall (n = 5158) | With AF (n = 2091) | Without AF (n = 3067) | P-value   |
|---------------------------------------|-------------------|-------------------|----------------------|-----------|
| Female                                | 2416 (46.8)       | 1025 (49.0)       | 1391 (45.4)          | 0.010     |
| Age, mean (SD), years                 | 68.4 (14.7)       | 70.7 (12.6)       | 66.8 (15.7)          | < 0.001   |
| Age group, years                      |                   |                   |                      | < 0.001   |
| < 40                                  | 271 (5.3)         | 46 (2.2)          | 225 (7.3)            |           |
| 40–49                                 | 341 (6.6)         | 99 (4.7)          | 242 (7.9)            |           |
| 50–59                                 | 638 (12.4)        | 236 (11.3)        | 402 (13.1)           |           |
| 60–69                                 | 1003 (19.4)       | 399 (19.1)        | 604 (19.7)           |           |
| 70–79                                 | 1744 (33.8)       | 799 (38.2)        | 945 (30.8)           |           |
| ≥ 80                                  | 1161 (22.5)       | 512 (24.5)        | 649 (21.2)           |           |
| Height, mean (SD), cm                 | 159.2 (17.0)      | 158.7 (18.7)      | 159.5 (15.8)         | 0.104     |
| Weight, mean (SD), kg                 | 60.1 (13.7)       | 60.0 (13.8)       | 60.2 (13.7)          | 0.536     |
| BMI, mean (SD), kg/m²                 | 23.1 (4.4)        | 23.1 (4.5)        | 23.2 (4.4)           | 0.759     |
| HF subtypes (n = 4968)                |                   |                   |                      | < 0.001   |
| HFpEF (EF ≥ 50%)                      | 1260 (25.4)       | 656 (32.6)        | 604 (20.4)           |           |
| HFmrEF (40% ≤ EF < 50%)               | 799 (16.1)        | 359 (17.9)        | 440 (14.9)           |           |
| HFrEF (EF < 40%)                      | 2909 (58.6)       | 995 (49.5)        | 1914 (64.7)          |           |
| Comorbidity at baseline               |                   |                   |                      |           |
| Hypertension                          | 3228 (62.6)       | 1302 (62.3)       | 1926 (62.8)          | 0.699     |
| Diabetes mellitus                     | 2082 (40.4)       | 719 (34.4)        | 1363 (44.4)          | < 0.001   |
| Previous stroke                       | 789 (15.3)        | 410 (19.6)        | 379 (12.4)           | < 0.001   |
| Previous chronic renal failure        | 732 (14.2)        | 259 (12.4)        | 473 (15.4)           | 0.002     |
| IHD                                   | 2237 (43.4)       | 627 (30.0)        | 1610 (52.5)          | < 0.001   |
| VHD                                   | 991 (19.2)        | 608 (29.1)        | 383 (12.5)           | < 0.001   |
| Cardiomyopathy                        | 1409 (27.3)       | 509 (24.3)        | 900 (29.3)           | < 0.001   |
| COPD                                  | 562 (10.9)        | 251 (12.0)        | 311 (10.1)           | 0.034     |
| Medications before discharge          |                   |                   |                      |           |
| Angiotensin-converting enzyme inhibitor| 1980 (38.4)       | 714 (34.1)        | 1266 (41.3)          | < 0.001   |
| Angiotensin receptor blockers         | 2372 (46.0)       | 926 (44.3)        | 1446 (47.1)          | 0.043     |
| Beta-blockers                         | 3012 (58.4)       | 1182 (56.5)       | 1830 (59.7)          | 0.025     |
| Aldosterone antagonist                | 2888 (56.0)       | 1235 (59.1)       | 1653 (53.9)          | 0.001     |
| Loop diuretics                        | 4721 (91.5)       | 1965 (94.0)       | 2756 (89.9)          | < 0.001   |
| Digoxin                               | 1708 (33.1)       | 1141 (54.6)       | 567 (18.5)           | < 0.001   |
| Warfarin                              | 1669 (32.4)       | 1268 (60.6)       | 401 (13.1)           | < 0.001   |
| Aspirin                               | 3362 (65.2)       | 1194 (57.1)       | 2168 (70.7)          | < 0.001   |
| Statin                                | 2432 (47.2)       | 779 (37.3)        | 1653 (53.9)          | < 0.001   |
| Smoking                               |                   |                   |                      | < 0.001   |
| Current smoker                        | 951 (18.4)        | 277 (13.2)        | 674 (22.0)           |           |
| Ex-smoker                             | 1057 (20.5)       | 444 (21.2)        | 613 (20.0)           |           |
| Never smoker                          | 3150 (61.1)       | 1370 (65.5)       | 1780 (58.0)          |           |
| Alcohol intake                        |                   |                   |                      | 0.288     |
| Heavy alcoholic                       | 356 (6.9)         | 153 (7.3)         | 203 (6.6)            |           |
| Social drinker                        | 1623 (31.5)       | 635 (30.4)        | 988 (32.2)           |           |
| Never drinker                         | 3179 (61.6)       | 1303 (62.3)       | 1876 (61.2)          |           |

Data are reported as n (%)

Abbreviations: AF atrial fibrillation, BMI body mass index, HF heart failure, EF ejection fraction, HFpEF heart failure with preserved ejection fraction, HFmrEF heart failure with mid-range ejection fraction, HFrEF heart failure with reduced ejection fraction, IHD ischemic heart disease, VHD valvular heart disease, COPD chronic obstructive pulmonary disease
Predictive accuracy of CHA2DS2-VASc score

At 1 year follow-up, each 1-point increase in CHA2DS2-VASc score, considered as a continuous variable, was associated with significantly increased risks of stroke in HF patients with (HR = 1.162, 95% CI = 1.028–1.313) and without (HR = 1.156, 95% CI = 1.006–1.328) AF, as well as significantly increased risks of all-cause death in HF patients with (HR = 1.165, 95% CI = 1.100–1.234) and without (HR = 1.213, 95% CI = 1.155–1.275) AF (Table 4). At 2 year follow-up, each 1-point increase in CHA2DS2-VASc score was also significantly associated with increased risk of stroke in HF patients with (HR = 1.237, 95% CI = 1.108–1.381) and without (HR = 1.144, 95% CI = 1.009–1.298) AF, and with significantly increased risk of all-cause death in HF patients with (HR = 1.192, 95% CI = 1.135–1.251) and without (HR = 1.216, 95% CI = 1.167–1.268) AF. The CHA2DS2-VASc score performed modestly in this population of patients with HF at 1 year follow-up. However, competing risk analysis showed that CHA2DS2-VASc score was not associated with increased risk of stroke in HF patients without AF. The C-indices for stroke in patients with and without AF were 0.598 (95% CI, 0.538–0.658) and 0.593 (95% CI, 0.534–0.652), respectively; and the C-indices for all-cause death in patients with and without AF were 0.600 (95% CI, 0.571–0.629) and 0.630 (95% CI, 0.606–0.653), respectively. The predictive ability after 2 years was slightly higher, but was still modest. The C-indices for stroke in patients with and without AF were 0.639 (95% CI, 0.585–0.694) and 0.613 (95% CI, 0.561–0.666), respectively; and the C-indices for all-cause death in patients with and without AF were 0.626 (95% CI, 0.600–0.652) and 0.635 (95% CI, 0.612–0.658), respectively. The predictive ability at endpoint in the KorAHF study population presented in Additional file 3.

Discussion

This study showed that CHA2DS2-VASc score was significantly associated with the risks of stroke and death in patients with HF, both with and without AF, and that CHA2DS2-VASc score was able to modestly predict the risk of stroke and death in these patients. This study also found that stroke mainly occurred during the early phase after hospitalization for HF. To our knowledge, this is the first study to evaluate the ability of CHA2DS2-VASc score to predict the risk of stroke and death in Asian patients with HF.

| Table 2 Incidence rates of stroke at 1 and 2 year follow-up in the KorAHF study population, stratified according to prior diagnosis of atrial fibrillation |
|----------------------------------|-----------------------------|-----------------------------|
| Characteristics                 | At 1 year follow-up         | At 2 year follow-up         |
|                                 | With AF (n = 2091)          | Without AF (n = 3067)       | With AF (n = 2091)          | Without AF (n = 3067)       |
|                                 | Patients (%) IR             | Patients (%) IR             | Patients (%) IR             | Patients (%) IR             |
| Overall                         | 94 (4.5) 5.74              | 86 (2.8) 3.55              | 116 (5.5) 3.96              | 103 (3.4) 2.37              |
| Age, years                      |                            |                            |                            |                            |
| < 40                            | 1 (2.2) 2.59               | 2 (0.9) 1.02               | 1 (2.2) 1.43               | 2 (0.9) 0.55               |
| 40–49                           | 1 (1.0) 1.25               | 9 (3.7) 4.55               | 2 (0.0) 1.34               | 9 (3.7) 2.43               |
| 50–59                           | 11 (4.7) 5.63              | 9 (2.2) 2.59               | 12 (5.1) 3.30              | 12 (3.0) 1.85              |
| 60–69                           | 16 (4.0) 4.83              | 17 (2.8) 3.49              | 18 (4.5) 2.94              | 23 (3.8) 2.59              |
| 70–79                           | 34 (4.3) 5.38              | 30 (3.2) 4.12              | 44 (5.5) 3.91              | 37 (3.9) 2.87              |
| ≥80                             | 31 (6.1) 8.62              | 19 (2.9) 4.10              | 39 (7.6) 6.43              | 20 (3.1) 2.56              |
| Sex                             |                            |                            |                            |                            |
| Male                            | 41 (3.8) 4.89              | 55 (3.3) 4.20              | 52 (4.9) 3.44              | 65 (3.9) 2.74              |
| Female                          | 53 (5.2) 6.63              | 31 (2.2) 2.79              | 64 (6.2) 4.53              | 38 (2.7) 1.93              |
| CHA2DS2-VASc score              |                            |                            |                            |                            |
| 1 (HF only)                     | 6 (4.3) 5.29               | 7 (3.3) 4.00               | 7 (5.1) 3.32               | 7 (3.3) 2.13               |
| 2                               | 9 (3.2) 3.79               | 4 (0.8) 0.93               | 9 (3.2) 2.03               | 5 (1.0) 0.62               |
| 3                               | 9 (2.6) 3.19               | 16 (3.3) 4.04              | 14 (4.1) 2.69              | 18 (3.7) 2.47              |
| 4                               | 21 (5.0) 6.61              | 14 (2.6) 3.26              | 21 (5.0) 3.71              | 21 (3.9) 2.73              |
| 5                               | 18 (4.3) 5.66              | 17 (2.9) 3.82              | 22 (5.2) 3.90              | 20 (3.4) 2.56              |
| 6                               | 14 (5.1) 6.91              | 16 (3.8) 5.04              | 22 (7.9) 6.36              | 17 (4.0) 3.07              |
| ≥7                              | 17 (7.7) 10.27             | 12 (3.8) 5.32              | 21 (9.5) 7.65              | 15 (4.7) 3.91              |

Incidence rates per 100 person-years

Abbreviations: AF atrial fibrillation, IR incidence rate
HF has a prevalence of approximately 1–2% among adult populations in developed countries, rising to ≥10% among individuals aged > 70 years [20]. In Korea, the prevalence of HF was 1.53% in 2013, and is expected to increase to 3.35% in 2040 [21]. In the present study, the 1 and 2 year all-cause mortality rates among patients with HF were 21.1 and 29.7%, respectively. By comparison, a previous study of individuals in the KorAHF registry reported that the 1, 2, and 3 year all-cause mortality rates were 18.2, 27.6, and 34.6%, respectively [15]. The discrepancy between these earlier results and ours is likely due, at least in part, to the exclusion from the present study of patients with a previous history of cancer. In addition, the present study population consisted of hospitalized patients with acute decompensation, a population with a relatively high mortality rate. For example, the European Society of Cardiology Heart Failure Pilot study showed that the 1 year all-cause mortality rates for hospitalized and stable/ambulatory HF patients were 17.4 and 7.2%, respectively [22], and a prospective observational cohort study in France reported that 20.8% of patients died within 1 year after the index hospitalization discharge [23]. HF-associated mortality rates have declined over the last 30 years, due to improvements in treatments and their implementation [20], but the mortality rate in patients with HF still remains high.

In the present study, the overall incidence rates of stroke during the first year after HF hospitalization in patients with and without AF were 4.5 and 2.8 per 100 person-years, respectively, rates higher than reported previously [12, 13]. For example, a nationwide prospective cohort study in Denmark reported that the incidence rates of ischemic stroke within 1 year after HF diagnosis were 2.0 and 1.0 per 100 person-years in patients with and without AF, respectively [12]. The difference may have been due to our inclusion of patients with more severe disease and/or to racial/ethnic differences in the risk of stroke. Indeed, among countries in the Organization for Economic Cooperation and Development (OECD), South Korea has a relatively high mortality rate from cerebrovascular diseases. Similar to the results from Denmark [12], we also found that the majority of strokes occurred relatively shortly after HF hospitalization, with 66.2% of all strokes occurring during the first year after HF hospitalization. Furthermore, the incidence rate of stroke during the first year after HF hospitalization was 3.5%, and the cumulative incidence during a mean

### Table 3 Incidence rates of death at 1 and 2 year follow-up in the KorAHF study population, stratified according to prior diagnosis of atrial fibrillation

| Characteristics | At 1 year follow-up | At 2 year follow-up |
|-----------------|---------------------|---------------------|
|                 | With AF (n = 2091)  | Without AF (n = 3067) | With AF (n = 2091) | Without AF (n = 3067) |
|                 | Patients (%) IR     | Patients (%) IR     | Patients (%) IR     | Patients (%) IR     |
| Overall         | 446 (21.3) 26.45    | 643 (21.0) 26.05    | 626 (29.9) 20.61    | 905 (29.5) 20.36    |
| Age, years      |                     |                     |                     |
| < 40            | 4 (8.7) 10.09       | 15 (6.7) 7.57       | 5 (10.9) 6.98       | 20 (8.9) 5.42       |
| 40–49           | 16 (16.2) 19.82     | 30 (12.4) 14.67     | 17 (17.2) 11.21     | 37 (15.3) 9.63      |
| 50–59           | 30 (12.7) 14.89     | 41 (10.2) 11.63     | 41 (17.4) 10.91     | 68 (16.9) 10.30     |
| 60–69           | 56 (14.0) 16.45     | 111 (18.4) 22.28    | 91 (22.8) 14.41     | 153 (25.3) 16.80    |
| 70–79           | 177 (22.2) 27.23    | 226 (23.9) 30.44    | 241 (30.2) 20.59    | 321 (34.0) 24.30    |
| ≥ 80            | 163 (31.8) 43.59    | 220 (33.9) 46.52    | 231 (45.1) 36.28    | 306 (47.1) 38.31    |
| Sex             |                     |                     |                     |
| Male            | 230 (21.6) 26.77    | 354 (21.1) 26.41    | 316 (29.6) 20.24    | 500 (29.8) 20.51    |
| Female          | 216 (21.1) 26.11    | 289 (20.8) 25.61    | 310 (30.2) 20.99    | 405 (29.1) 20.19    |
| CHA2DS2-VASc score |                   |                     |                     |
| 1 (HF only)     | 17 (12.3) 14.56     | 20 (9.5) 11.03      | 20 (14.5) 9.22      | 28 (13.3) 8.19      |
| 2               | 32 (11.5) 13.13     | 59 (11.7) 13.64     | 45 (16.1) 9.87      | 82 (16.2) 10.15     |
| 3               | 63 (18.5) 22.09     | 72 (14.8) 17.60     | 83 (24.3) 15.68     | 108 (22.1) 14.35    |
| 4               | 95 (22.8) 28.80     | 115 (21.3) 26.44    | 138 (33.2) 23.25    | 168 (31.1) 21.46    |
| 5               | 92 (21.9) 28.00     | 148 (25.5) 32.66    | 135 (32.1) 22.96    | 209 (36.0) 26.25    |
| 6               | 79 (28.5) 37.57     | 122 (28.8) 37.53    | 111 (40.1) 30.65    | 155 (36.6) 27.32    |
| ≥ 7             | 68 (30.9) 39.58     | 107 (33.8) 45.97    | 94 (42.7) 32.21     | 155 (48.9) 39.21    |

Incidence rates per 100 person-years

Abbreviations: AF atrial fibrillation, IR incidence rate
follow-up of 2.3 years was 5.3%. These findings indicate that early intervention is essential for prevention of stroke in patients with HF.

Risk prediction models involving readily available clinical variables may be useful in preventing stroke and death in patients with HF. The CHA$_2$DS$_2$-VASc score [8] is an easily determined clinical risk score commonly used to stratify stroke risk in patients with AF [9]. The 2012 European Society of Cardiology (ESC) and the Korean Heart Rhythm Society (KHRS) guidelines recommend the use of CHA$_2$DS$_2$-VASc score to determine the necessity of treatment with an oral anticoagulant (OAC) or a non-vitamin K antagonist oral anticoagulant (NOAC) to prevent stroke [9, 24]. CHA$_2$DS$_2$-VASc score has been used to predict ischemic stroke, thromboembolism, and death in subjects without AF [10, 11] and in patients with incident HF with or without AF, although its predictive accuracy was modest (C-statistics 0.6–0.7) [12]. In addition, CHA$_2$DS$_2$-VASc score was reported to have only modest predictive accuracy for death and stroke in patients with systolic HF in sinus rhythm [13]. Similarly, a nationwide retrospective study of the Korea National Health Insurance Corporation sample cohort showed that the CHA$_2$DS$_2$-VASc score could help stratify stroke risk for individual HF patients (C-statistics 0.657), but its predictive ability was lower in patients with than without AF [25]. We found that CHA$_2$DS$_2$-VASc score, as a continuous variable, was able to modestly predict the risks of stroke and death in patients with HF with AF, and that CHA$_2$DS$_2$-VASc score was dependent on the length of follow-up. Although these initial results indicate the potential usefulness of CHA$_2$DS$_2$-VASc score, its direct clinical utility in stratifying stroke risk stratification in patients with HF remains unclear. Additional studies, testing the ability of a modified CHA$_2$DS$_2$-VASc score to predict the development of stroke and death in patients with HF, are needed.

**Table 4** Assessment of the ability of CHA$_2$DS$_2$-VASc score to predict stroke and death at 1 and 2 year follow-up in the KorAHF study population, stratified according to prior diagnosis of atrial fibrillation

| Characteristics | Overall (n = 5158) | With AF (n = 2091) | Without AF (n = 3067) |
|-----------------|-------------------|--------------------|--------------------|
|                 | HR (95% CI)       | P-value            | HR (95% CI)       | P-value            |
| **At 1 year**   |                   |                    |                   |
| Stroke          |                   |                    |                   |
| Model 1         | 1.157 (1.070–1.253) | < 0.001            | 1.165 (1.043–1.302) | 0.007            |
| Model 2         | 1.173 (1.072–1.283) | 0.001              | 1.162 (1.028–1.313) | 0.017            |
| Model 3         | 1.151 (1.050–1.260) | 0.003              | 1.140 (1.005–1.290) | 0.042            |
| C-index (95% CI)$^a$ | 0.595 (0.536–0.654) |                    | 0.598 (0.538–0.658) | 0.593 (0.534–0.652) |
| Death           |                   |                    |                   |
| Model 1         | 1.212 (1.174–1.251) | < 0.001            | 1.180 (1.121–1.242) | < 0.001          |
| Model 2         | 1.196 (1.153–1.241) | < 0.001            | 1.165 (1.100–1.234) | < 0.001          |
| C-index (95% CI)$^a$ | 0.618 (0.599–0.636) |                    | 0.600 (0.571–0.629) | 0.630 (0.606–0.653) |
| **At 2 year**   |                   |                    |                   |
| Stroke          |                   |                    |                   |
| Model 1         | 1.187 (1.105–1.275) | < 0.001            | 1.212 (1.097–1.340) | < 0.001          |
| Model 2         | 1.210 (1.116–1.313) | < 0.001            | 1.237 (1.108–1.381) | < 0.001          |
| Model 3         | 1.181 (1.088–1.280) | < 0.001            | 1.204 (1.077–1.350) | 0.001            |
| C-index (95% CI)$^a$ | 0.626 (0.573–0.680) |                    | 0.639 (0.585–0.694) | 0.613 (0.561–0.666) |
| Death           |                   |                    |                   |
| Model 1         | 1.227 (1.194–1.260) | < 0.001            | 1.207 (1.156–1.260) | < 0.001          |
| Model 2         | 1.210 (1.173–1.248) | < 0.001            | 1.192 (1.135–1.251) | < 0.001          |
| C-index (95% CI)$^a$ | 0.635 (0.612–0.658) |                    | 0.626 (0.600–0.652) | 0.635 (0.612–0.658) |

Model 1: unadjusted model
Model 2: adjusted for previous chronic renal failure, ischemic heart disease, valvular heart disease, cardiomyopathy, chronic obstructive pulmonary disease (COPD), medications (Angiotensin-converting enzyme inhibitor, Angiotensin receptor blockers, Beta-blockers, Aldosterone antagonist, Loop diuretics, Digoxin, Warfarin, Aspirin, Statin), and smoking
Model 3: competing risk model adjusted for previous chronic renal failure, ischemic heart disease, valvular heart disease, cardiomyopathy, chronic obstructive pulmonary disease (COPD), medications (Angiotensin-converting enzyme inhibitor, Angiotensin receptor blockers, Beta-blockers, Aldosterone antagonist, Loop diuretics, Digoxin, Warfarin, Aspirin, Statin), and smoking after considering all-cause death as a competing risk

Abbreviations: AF: atrial fibrillation, HR: hazard ratio, CI: confidence interval

$^a$ From time-receiver operative characteristic (ROC) curve analysis
This study had several limitations. First, patients with AF were included both recurrence and no recurrence patients, however we could not distinguish for these groups. Second, patients with stroke in this study included those with both ischemic and hemorrhagic stroke, as the sample size was too small to statistically analyze each outcome and stroke were not distinguished between ischemic and hemorrhagic stroke. Third, we could not evaluate the use of non-vitamin K antagonist oral anticoagulant (NOAC) therapy, because it have been reimbursed by the Korean National Health Insurance since 2015. Fourth, because the KorAHF registry enrolled patients who were hospitalized for acute HF, our results may have overestimated the predictive ability of the CHA2DS2-VASc score. Also, the CHA2DS2-VASc score might be more reasonably predictable in chronic stable HF patients compared to acute HF patients. Additional studies including patients with stable HF are required. However, this study reported risks 1 and 2 years after discharge, as well as after overall follow-up, suggesting that these results are comparable with the general HF population.

Despite these limitations, this study had several strengths. First, we used the KorAHF registry, a prospective, previously validated cohort study containing a large number of patients. Second, to our knowledge, this study is the first to investigate the risks of stroke and death, which are important when investigating the performance of risk scores in populations with a high mortality rate [26, 27], in patients with HF using CHA2DS2-VASc score. In addition, this study was the first to evaluate the ability of the CHA2DS2-VASc score to predict the risks of stroke and death in Asian patients with HF, with and without AF.

**Conclusions**

Evaluation of patients in the KorAHF registry showed that the majority of strokes occurred relatively shortly after hospitalization for HF and that mortality rates in patients with HF remain high. Thus, early treatment after HF to prevent stroke is essential. CHA2DS2-VASc score was significantly associated with the risks of stroke in patients with acute HF patients with AF, and it was significantly associated with the risks of death in both HF patients with and without AF. Because CHA2DS2–VASc score had only a modest ability to predict the risk of stroke in these patients, the clinical utility of the CHA2DS2-VASc score in patients with HF remains to be determined. Future studies using a modified CHA2DS2–VASc score to predict the risks of stroke and death in patients with HF are needed.

**Additional files**

Additional file 1: Incidence rates of stroke and death at endpoint in the KorAHF study population, stratified according to prior diagnosis of atrial fibrillation (PDF 130 kb)

**Abbreviations**

AF: Atrial fibrillation; AUC: Area under the receiver operating characteristic curve; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; ESC: European society of cardiology; HF: Heart failure; HR: Hazard ratio; IHD: Ischemic heart disease; KHIRS: Korean Heart Rhythm Society; KorAHF: The Korean acute heart failure; NOAC: Non-vitamin K antagonist oral anticoagulant; OAC: Oral anticoagulant; OECD: Organization for Economic Cooperation and Development; ROC: Receiver-operating characteristic; VHD: Valvular heart disease

**Acknowledgements**

The authors would like to thank all the staff and patients who have contributed data via the KorAHF registry.

**Authors’ contributions**

MKS participated in the design of the study, performed the statistical analysis, interpreted the findings, and drafted the manuscript. NKL contributed to the study design and discussion. HYP participated in the design of the study, was involved in revising the manuscript for important intellectual content, and gave final approval of the version to be published. All authors have read and approved the final manuscript.

**Funding**

This work was supported by the Korea National Institute of Health intramural research grant, 4800–4845-302 (2017-NI63001–00).

**Availability of data and materials**

Legal restrictions prohibit us from making our dataset publicly available. We were allowed to use the data from a South Korean government agency, Korea Centers for Disease Control (KCDC) on requested topics and we are not allowed to open the data to the public yet. The KorAHF registry is strictly managed by KCDC, which provides the data to researchers at the contribution of each institution to the cohort enrollment. Those who are interested in related data may contact and request the data from KCDC in South Korea (e-mail: nklim@korea.kr).

The information of KorAHF registry can be obtained the following site: http://clinicaltrials.gov/ct2/show/NCT01389843

**Ethics approval and consent to participate**

This study protocol was approved by the Ethics Committee/Institutional Review Board (IRB No. 1102–072-352) of each participating hospital: Seoul National University Hospital; Seoul National University Bundang Hospital; Chungbuk National University hospital; Chonnam National University Hospital; Samsung Medical Center; Asan Medical Center; Kyungpook National University hospital; Catholic University St. Mary’s Hospital; Yonsei University Severance Hospital; Wonju Christian Hospital. Written informed consent was obtained from each patient. If patients were unable to provide consent due to disease severity or other reasons, informed consent was obtained from relatives or a legal guardian.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Division for Cardiovascular Diseases, Korea National Institute of Health, 187 OsongSaengmyeong2-Ro, Osong-Eup, Cheongju, Chungcheongbuk-Do, Republic of Korea. 2Center for Genome Science, Korea National Institute of Health, 187 OsongSaengmyeong2-Ro, Osong-Eup, Cheongju, Chungcheongbuk-Do, Republic of Korea.

**Additional file 1:** Frequency of cardiomyopathy according to baseline CHA2DS2-VASc score (PDF 44 kb)

**Additional file 2:** Assessment of the ability of CHA2DS2-VASc score to predict stroke and death at endpoint in the KorAHF study population, stratified according to prior diagnosis of atrial fibrillation (PDF 83 kb)

**Additional file 3:** Assessment of the ability of CHA2DS2-VASc score to predict stroke and death at endpoint in the KorAHF study population, stratified according to prior diagnosis of atrial fibrillation (PDF 83 kb)
References

1. Ponikowski P, Voors AA, Anker SD, et al. Authors/task force members and document reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18:891–957. doi:https://doi.org/10.1002/ejhf.592.

2. Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J. 2000;27(3):257–67.

3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–8.

4. Alberts JP, Bos MJ, Koudstaal P, et al. Heart failure and the risk of the Rotterdam study. Eur J Epidemiol. 2010;25:807–12.

5. Lip GY, Rasmussen LH, Skjøth F, et al. Stroke and mortality in patients with incident heart failure: the diet, Cancer and health (DCH) cohort study. BMJ Open. 2011;2:1–10.

6. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N.

7. Kaarisalo MM, Immonen-Raiha P, Marttila RJ, et al. Atrial fibrillation and stroke. Mortality and cause of death after the first acute ischemic stroke. Stroke. 1997;28:311–5.

8. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.

9. Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for practice guidelines. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.

10. Lip GYH, Lin H-J, Chien K-L, et al. Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population the Chin-Shan community cohort study. Int J Cardiol. 2013;168:414–9.

11. Mitchell LB, Southern DA, Galbraith D, et al. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014;100:1524–30.

12. Melgaard L, Gorst-Rasmussen A, Lane DA, et al. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314:1030–8.

13. Ye S, Qian M, Zhao B, et al. CHA2DS2-VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. Eur J Heart Fail. 2016;18:1261–6.

14. Lee SE, Cho HJ, Lee HY, et al. A multicenter cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean acute heart failure (KoaHF) registry. Eur J Heart Fail. 2014;16:700–8.

15. Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean acute heart failure registry (KoaHF). Korean Circ J. 2017;47:341–53.

16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

17. Chambless LE, Diao G. Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med. 2006;25:3474–86.

18. “timeROC” package. Available at: https://cran.r-project.org/web/packages/timeROC/index.html. Accessed 21 July, 2015.

19. Scrucca L, Santucci A, Avenza F. Regression modeling of competing risk using R. an in depth guide for clinicians. Bone Marrow Transplant. 2010;45:1388–95.

20. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129–300.

21. Lee JH, Lim NK, Cho MC, et al. Epidemiology of heart failure in Korea: present and future. Korean Circ J. 2016;46:658–63.